Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Monash IVF (MVF) says the IVF market is recovering

Monash IVF (ASX:MVF) shares are down 1% despite announcing that it is seeing a recovery in the IVF market. 

Monash IVF (ASX: MVF) shares are down 1% despite announcing that it is seeing a recovery in the IVF market.

What is Monash IVF?

Monash IVF Group is a leading provider of assisted reproductive services. Basically, they assist couples who wish to have children but for one reason or another, have difficulty in conceiving a child naturally. Technology has come a long way since the first IVF pregnancy back in 1973 and Monash IVF is at the forefront of these developments.

What did the company announce?

Monash IVF said that there has been pent up patient demand after IVF treatments restarted on 27 April 2020. Compared to the prior corresponding period and pre-COVID-19 levels, the company has seen strong growth.

From 18 May 2020 to 30 June 2020 the company has seen stimulated cycle growth of 25%. There has been growth across all key markets in Australia. The company is also pleased by positive early signs from the new patient pipeline returning to normal levels.

The company’s women’s ultrasound business remained open during April, May and June. Ultrasound can volumes were down around 5% compared to a year ago. However, strict infection control and hygiene measures has increased costs.

Internationally, the Malaysian IVF business is still being impacted by restrictions, though these were eased on 9 June 2020. Trading conditions are improving, but still yet to return to pre COVID-19 levels.

At 30 June 2020 the company is expecting net debt to be less than $10 million after its recent $80 million capital raising. The company will pay its deferred HY20 dividend on 2 October 2020.

The company expects the second half of FY20 to show adjusted profit of $4.6 million, down 55% because of COVID-19. Therefore, the company is expecting adjusted FY20 net profit to be $14 million.

I’m glad to see that the company is recovering, but I’m not sure if I’d invest in it. Cheap IVF competition is rising and an Australian recession could dent medium term IVF demand.

[ls_content_block id=”14945″ para=”paragraphs”]

Disclosure: At the time of writing, Jaz doesn’t own shares in any of the businesses mentioned. 

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content